摘要
目的探讨伊托必利促胃肠动力干预措施对长期卧床老年患者肺部感染的防治价值。方法采用前瞻性、随机、对照设计,将年龄>60岁、长期卧床、神志清楚、反流性疾病问卷阳性患者分为药物治疗组(伊托必利,A组)和对照组(B组),比较两组患者吸入性肺炎(AP)发病率、医院内获得性肺炎(HAP)发病率、相对危险度、肺部感染的粗死亡率、归因死亡率、临床肺部感染评分、急性生理与慢性健康评分系统Ⅱ评分、住院时间及肺部感染持续时间。结果 A组HAP发病率低于B组(P<0.05)。两组患者肺部感染的粗死亡率、归因死亡率、CPIS与APACHEⅡ评分的差异无统计学意义(P>0.05)。A组住院时间、感染持续时间均较B组短,差异有统计学意义(P<0.05)。结论伊托必利可降低长期卧床胃食管反流高风险的老年患者HAP发病率,缩短患者住院时间及肺部感染持续时间,但不影响患者的死亡率。
Objective To explore the value of Ropride prokinetic intervention measures to control long-term pulmonary infection in elderly patients in long-term bed. Methods The age〉60 years old, long-term bedridden, sane, reflux disease questionnaire positive patients were divided into drug group 0topride treated, A group） and control group （B group） in a prospective, randomized, controlled design. Compared the 2 groups of patients with the incidence of aspiration pneumonia （AP）, acquired nosocomial pneumonia （HAP）, relative risk, crude mortality, pulmonary infection attributable mortality, clinical pulmonary infection score, acute physiology and chronic health score system Ⅱ score, duration of hospitalization time and pulmonary infection. Results In A group, the incidence rate of HAP, the duration of hospitalization time and pulmonary infection was less than in B group （P〈0.05）. The 2 groups were no statistical significance in the the incidence rate of HAP crude mortality, pulmonary infection attributable mortality, clinical pulmonary infection score, acute physiology and chronic health score system II score （P〉0.05）. Conclusion Itopride may reduce the incidence of HAP in elderly bed ridden patients with gastroesophageal reflux of high risk rate, shorten the time and duration of hospitalization in patients with pulmonary infection, but did not affect the mortality of patients.
出处
《中华临床医师杂志（电子版）》
CAS
2015年第16期33-36,共4页
Chinese Journal of Clinicians(Electronic Edition)
基金
福建省卫生厅青年科研课题(2011-2-44)
关键词
伊托必利
长期卧床
呼吸道感染
发病率
死亡率
Itopride
Long-term bed gerontal
Respiratory tract infections
Incidence
Mortality
